Metcela

MetcelaMetcela
Metcela

Metcela

Developing regenerative medicine solutions using stem cell technology.

Website
DR 38Speed 342012ActiveTokyo, Japan
Rate
Advertise here

About

Metcela is a clinical-stage biotechnology company focused on developing regenerative cell therapies for chronic diseases, particularly cardiovascular conditions like heart failure. Their lead asset, MTC001, utilizes autologous cardiac fibroblasts to repair damaged heart tissue, with a proprietary delivery system for precise administration. They also acquired Japan Regenerative Medicine Co., Ltd., which develops cardiac stem cell-based therapy for pediatric congenital heart diseases.
Frequently asked

What does Metcela do?

Metcela is a clinical-stage biotechnology company focused on developing regenerative cell therapies for chronic diseases, particularly cardiovascular conditions like heart failure. Their lead asset, MTC001, utilizes autologous cardiac fibroblasts to repair damaged heart tissue, with a proprietary delivery system for precise administration. They also acquired Japan Regenerative Medicine Co., Ltd., which develops cardiac stem cell-based therapy for pediatric congenital heart diseases.

What is Metcela's valuation?

StartupHub estimates Metcela's effective valuation at $145.5M (range $91.4M to $219.4M, 10% confidence), based on comparable companies in the sector.

How much funding has Metcela raised?

Metcela has raised a total of $37M in funding. The most recent round on record is Series C.

Where is Metcela headquartered?

Metcela is headquartered in Tokyo, Japan.

When was Metcela founded?

Metcela was founded in 2012.

Comments

No comments yet. Be the first to share your take.